---
layout: default
title: Alpha -Tocopherol Beta -Sitosterol Ascorbic Acid B
parent: 僅模型預測 (L5)
nav_order: 243
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Beta -Sitosterol Ascorbic Acid B
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Component Botanical Mixture: Drug Repurposing Evaluation Not Feasible

## One-Sentence Summary

This submission contains a seven-component botanical and nutraceutical mixture — α-Tocopherol, β-Sitosterol, Ascorbic Acid, Beta Carotene, Houttuynia Cordata, Nattokinase, and Rutin — with no current regulatory approval and no single unified DrugBank identity. The TxGNN model was unable to generate any repurposing prediction for this entry, and core data prerequisites (original indications, mechanism of action, regulatory licenses) are all absent. Evaluation cannot proceed under the standard drug repurposing framework until the candidate is decomposed or re-submitted as individual components.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN prediction unavailable |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A (prerequisite data missing; below L5) |
| Taiwan Market Status | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN model operates on individual DrugBank-mapped small molecules or biologics. Each component of this submission is a distinct chemical entity with its own pharmacology:

| Component | Class | Known Role |
|-----------|-------|-----------|
| α-Tocopherol | Fat-soluble vitamin (Vitamin E) | Antioxidant, membrane stabilizer |
| β-Sitosterol | Plant sterol | Cholesterol-lowering, BPH symptom relief |
| Ascorbic Acid | Water-soluble vitamin (Vitamin C) | Antioxidant, collagen biosynthesis cofactor |
| Beta Carotene | Carotenoid (Vitamin A precursor) | Antioxidant, immune modulation |
| Houttuynia Cordata Top | Medicinal herb (魚腥草) | Anti-inflammatory, antimicrobial (traditional use) |
| Nattokinase | Serine protease enzyme | Fibrinolysis, cardiovascular benefit |
| Rutin | Flavonoid glycoside | Antioxidant, vascular protection, anti-inflammatory |

Because no unified DrugBank ID could be assigned to this multi-component mixture, TxGNN's knowledge graph traversal could not identify a node to anchor the repurposing query. As a result, `predicted_indications` is empty and no scored disease candidates were returned.

Additionally, the combination's pharmacological profile is additive at best — each ingredient acts through a different mechanism. This further limits the applicability of a single-entity repurposing model.

---

## Safety Considerations

Please refer to the package insert for safety information. No drug interaction data was found for this combined formulation, and warnings and contraindication data were not available in the current Evidence Pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model requires a DrugBank-mapped single agent as input. This submission presents a seven-ingredient mixture with no regulatory license, no original indication, and no mechanism-of-action data — none of the minimum prerequisites for a repurposing evaluation are met.

**To proceed, the following is needed:**

- **Decompose the candidate**: Resubmit each of the seven ingredients separately (e.g., Nattokinase, Rutin, β-Sitosterol) so TxGNN can generate per-component predictions. The most pharmacologically active and DrugBank-registered components (Nattokinase, Rutin, β-Sitosterol, α-Tocopherol) are the most likely to yield usable predictions.
- **Assign DrugBank IDs**: Resolve DrugBank identifiers for each mappable ingredient before re-running the pipeline. The query log indicates one DrugBank result was returned (`result_count: 1`), but it is unclear which component matched — this needs to be disambiguated.
- **Clarify product intent**: Determine whether this is a registered health supplement, a traditional Chinese medicine (TCM) formulation, or an investigational combination product. The regulatory pathway differs significantly between these categories.
- **Obtain package insert or product monograph**: Required to assess safety warnings and contraindications before any indication expansion study is designed.
- **Define a primary indication hypothesis**: If a specific therapeutic area (e.g., cardiovascular protection via Nattokinase + Rutin, or antioxidant support via Vitamins C/E + Beta Carotene) is the strategic focus, a targeted literature review can be conducted even without TxGNN output.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

